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I
n this issue of Diabetes, Grey and colleagues (1)
demonstrate that therapeutic B-cell depletion delays
diabetes onset and reduces diabetes incidence in
NOD mice. B-cell depletion in pre-diabetic NOD
mice was accomplished using an extended regime of
recombinant B-cell maturation antigen (BCMA)-Fc chi-
merized protein that targets B-lymphocyte stimulator
(BLyS)/B-cell–activating factor of the tumor necrosis fac-
tor family (BAFF)—a cytokine critical for maintenance of
the peripheral B-cell pool. This follows recent studies
demonstrating signiﬁcant effects of B-cell depletion on
diabetes onset and severity (2–5); however, no other
studies have reported profound and complete protection
from hyperglycemia as observed here. Following B-cell
depletion therapy during 9–15 weeks of age, NOD mice
remained diabetes free for 50 weeks of age, even after
B-cell reconstitution. An increase in CD25
Foxp3
CD4

regulatory T-cells (Tregs) following B-cell depletion may
mediate prolonged tolerance given that the CD25 mono-
clonal antibody (mAb) treatment neutralized the long-term
therapeutic beneﬁts of B-cell depletion (Fig. 1). This
mechanism may explain why B-cell–deﬁcient NOD.MT
mice do not develop hyperglycemia given that autoim-
mune diabetes was also precipitated in these mice by Treg
depletion.
Most diabetes-modifying immunotherapies target the
T-cell compartment directly because -cell destruction is
primarily mediated by CD4
 and CD8
 T-cells. Examples
include T-cell depletion, blockade of T-cell costimulation,
and Treg induction. Therapies that reduce antigen-speciﬁc
T-cell clonal expansion have profound effects during the
pre-diabetic stages of disease, whereas few therapies
reverse disease once the clinical manifestations of diabe-
tes are evident. This limitation appears to hold for B-cell–
directed therapies in NOD mice as well. Genetically,
B-cell–deﬁcient NOD mice generally lack islet inﬁltration
or insulitis and are free of overt diabetes (6–9). Likewise,
B-cell depletion by anti- antibody given from birth abro-
gates insulitis development in NOD mice (10). Recent
B-cell depletion studies in NOD mice have included an
anti-BLyS/BAFF mAb (3), anti-mouse CD20 mAb (2), anti-
human CD20 mAb in human CD20 transgenic NOD mice
(4), and anti-CD22 immunotoxin (5), which all target
mature B-cells. While each study highlights particular
ﬁndings or interpretations, the main observation is that the
absence of B-cells alters an early trigger for diabetes
onset, with the consistent conclusion that disease does not
progress in the absence of B-cells. Whether the remark-
able long-term tolerance indicated in the current study
results from features unique to the BCMA-Fc chimerized
protein is difﬁcult to conclude because all of the reported
B-cell depletion strategies have varied in approach, timing,
and analysis among individual NOD mouse colonies.
Nonetheless, now that B-cell depletion strategies with
potential clinical efﬁcacy have been found, standardized
guidelines for side-by-side comparisons in NOD mice
should be developed to identify important differences
between therapeutic approaches and results.
B-cells are among the earliest cells to inﬁltrate the
pancreatic islets of NOD mice, and autoantibodies against
islet antigens indicate disease onset in humans and mice
(11). Despite this, autoantibody production is not sufﬁcient
to initiate disease and is disconnected from the occur-
rence of diabetes and insulitis (11). Rather, B-cells are
multifunctional and are crucial antigen-presenting cells
(APCs) for priming proinﬂammatory T-cell responses to
-cell antigens (12–16). Thereby, obligatory B-cell APC
function may set the stage for systemic autoreactivity in
NOD mice because B-cell selection (17) and innate cell
APC function are impaired (18) in NOD mice (Fig. 1).
Consistent with this, diabetes resistance in congenitally
B-cell–deﬁcient NOD mice is lost following B-cell recon-
stitution (9,12). It is encouraging that the return of B-cells
following prolonged depletion in the current study did not
alter diabetes resistance given that the effect of mature
B-cell depletion on the peripheral B-cell repertoire re-
mains an open question. Presumably, unselected and
potentially autoreactive pre–B-cells and immature B-cells
that were not depleted during therapy repopulate the
periphery. For this, pre–B-cell and B-cell depletion using
CD19-directed therapies may have advantages (19). Be-
cause regulatory B-cells (B10-cells) also signiﬁcantly affect
autoimmunity (20), it will be important to determine
whether they represent a signiﬁcant component of the
reconstituted B-cell pool. Nonetheless, B-cell depletion
before disease onset may induce long-term tolerance
through Tregs—a possibility that opens new avenues for
investigation.
Transient B-cell depletion after the ﬁrst signs of disease
onset using anti-BLyS mAb also arrests diabetes progres-
sion and maintains NOD mice in a “honeymoon” state for
extended periods (3). Because Treg numbers did not
change 10 weeks posttreatment, the honeymoon was
attributed to enhanced B-cell competition and selection as
a result of limited BLyS/BAFF availability. However, that
other B-cell depletion therapies similarly reduce diabetes
incidence (2,4,5) argues that immediate -cell protection
results from changes in available APCs for autoreactive
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induce Treg expansion beyond that of pathogenic effector
T-cells (Fig. 1). Future studies are needed to determine
whether B-cell depletion uniformly induces Tregs and
how. The effect of BCMA-Fc treatment during later stages
of insulitis will also require further examination. If Tregs
do accumulate as suggested by Grey and colleagues, B-cell
depletion may be curative when administered before ex-
tensive loss of pancreatic -cell function because immune
regulatory mechanisms will not be beneﬁcial once -cell
destruction is complete, except for subsequent islet
transplants.
In summary, “Plan A” has shown that B-cell depletion is
a powerful therapeutic tool for reducing diabetes severity
and arresting islet destruction in NOD mice. This advance
in understanding diabetes onset and progression provides
the basis for “Plan B”: identifying the optimal strategy for
targeting B-cells for therapeutic beneﬁt. Whether this
involves the modulation of APC–T-cell interactions, the
induction of regulatory B- and T-cell subsets, or both
remains unanswered. Given the demonstrated importance
of both T- and B-cells in diabetes initiation and pathogen-
esis, it is likely that modulating both arms of the adaptive
immune response will be key for the development of
protective immunotherapies.
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FIG. 1. Model for autoantigen presentation in B-cell–depleted NOD mice. Autoantigen presentation is normally balanced between B-cells and
dendritic cells (DCs) in mice (16). A: NOD autoantigen presentation. However, B-cell cognate presentation of pancreatic autoantigens may
dominate in NOD mice because B-cell selection (17) and innate cell APC function are impaired (18). As a result, B-cell–driven pathogenic CD4

T-cell expansion and effector function leads to -cell destruction and insulin deﬁciency. B: Presentation without B-cells. Mature B-cell depletion
in NOD mice eliminates the initiating role of B-cells in disease pathogenesis but shifts antigen presentation to other APCs that may reduce CD4

T-cell activation in favor of Treg induction or expansion and lead to a tolerogenic state or honeymoon period without disease. C: Following B-cell
reconstitution, previously induced Tregs may limit autoreactive T-cell activation and expansion, thereby enforcing long-term tolerance and
protection from diabetes onset. Teff, effector T-cell.
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